Veradermics develops VDPHL01, an oral, non-hormonal treatment for hair loss, from its base in New Haven, Connecticut. MANE reports earnings on Tue, Nov 10, 2026. In the past 30 days there were 1 dark pool print.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 22 | B. Riley Securities | Target raised | Buy | |
| Oct 19 | Needham | Target raised | Buy | |
| Jul 16 | Citigroup | Target raised | Buy | |
| Jul 15 | Needham | Target raised | Buy | |
| Jul 15 | B. Riley Securities | Initiated | Buy |
Whale Options Flow
90DNo whale options trades in MANE in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MANE is in one of them and how their past MANE trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered MANE in an article yet. Here's the latest on the wider market.
About Veradermics
Veradermics is a biopharmaceutical company based in New Haven, Connecticut, that is developing treatments for hair loss. Its main product in development, VDPHL01, is an oral, extended-release form of minoxidil, a drug already used to grow hair, and it is designed to be non-hormonal. The company is running clinical trials in men and women with this condition and does not yet have an approved product. Its target customers are patients with hair loss and the dermatologists who treat them.
- Headquarters
- New Haven, CT